This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kapoor, A. Articles by Delwart, E. L. Search for Related Content PubMed PubMed Citation Articles by Kapoor, A. Articles by Delwart, E. L.

Sequencing-Based Detection of Low-Frequency Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by an RNA/DNA Heteroduplex Generator-Tracking Assay

Department of Medicine, University of California San Francisco,¹ Blood Systems Research Institute, San Francisco,² Department of Medicine, Stanford University, Stanford, California,³ Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan⁴

Received 19 November 2003/ Accepted 20 February 2004

Drug-resistant viruses may be present as minority variants during early treatment failures or following discontinuation of failed antiretroviral regimens. A limitation of the traditional direct PCR population sequencing method is its inability to detect human immunodeficiency virus type 1 (HIV-1) variants present at frequencies lower than 20%. A drug resistance genotyping assay based on the isolation and DNA sequencing of minority HIV protease variants is presented here. A multiple-codon-specific heteroduplex generator probe was constructed to improve the separation of HIV protease genes varying in sequence at 12 codons associated with resistance to protease inhibitors. Using an RNA molecule as probe allowed the simple sequencing of protease variants isolated as RNA/DNA heteroduplexes with different electrophoretic mobilities. The protease gene RNA heteroduplex generator-tracking assay (RNA-HTA) was tested on plasma quasispecies from 21 HIV-1-infected persons in whom one or more protease resistance mutations emerged during therapy or following initiation of salvage regimens. In 11 of 21 cases, RNA-HTA testing of virus from the first episode of virologic failure identified protease resistance mutations not seen by population-based PCR sequencing. In 8 of these 11 cases, all of the low-frequency drug resistance mutations detected exclusively by RNA-HTA during the first episode became detectable by population-based PCR sequencing at the later time point. Distinct sets of protease mutations could be linked on different genomes in patients with high-frequency protease gene lineages. The enhanced detection of minority drug resistance variants using a sequencing-based assay may improve the efficacy of genotype-assisted salvage therapies.

This article has been cited by other articles:

• Lalonde, M. S., Troyer, R. M., Syed, A. R., Bulime, S., Demers, K., Bajunirwe, F., Arts, E. J. (2007). Sensitive Oligonucleotide Ligation Assay for Low-Level Detection of Nevirapine Resistance Mutations in Human Immunodeficiency Virus Type 1 Quasispecies. J. Clin. Microbiol. 45: 2604-2615 [Abstract] [Full Text]  
• Wang, C., Mitsuya, Y., Gharizadeh, B., Ronaghi, M., Shafer, R. W. (2007). Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance. Genome Res. 17: 1195-1201 [Abstract] [Full Text]  
• Fernandez, G., Clotet, B., Martinez, M. A. (2007). Fitness Landscape of Human Immunodeficiency Virus Type 1 Protease Quasispecies. J. Virol. 81: 2485-2496 [Abstract] [Full Text]  
• Senescau, A., Berry, A., Benoit-Vical, F., Landt, O., Fabre, R., Lelievre, J., Cassaing, S., Magnaval, J.-F. (2005). Use of a Locked-Nucleic-Acid Oligomer in the Clamped-Probe Assay for Detection of a Minority Pfcrt K76T Mutant Population of Plasmodium falciparum. J. Clin. Microbiol. 43: 3304-3308 [Abstract] [Full Text]